Despite the ability of second- and third-generation ALK inhibitors to overcome crizotinib resistance in ALK fusion-positive NSCLC, resistance to these compounds has been shown to arise through secondary point mutations in the ALK kinase domain [93,132,133,134,135]. This evidence concerns the gene ALK and non-small cell lung carcinoma.